A 50-year journey to cure childhood acute lymphoblastic leukemia.

A 50-year journey to cure childhood acute lymphoblastic leukemia.
复制标题

DOI:
10.1053/j.seminhematol.2013.06.007
复制
发表时间:
2013-07
影响因子:
3.6
通讯作者:
Evans WE
Evans WE
中科院分区:
医学3区
文献类型:
--
作者:
Pui CH;Evans WE

文献摘要

参考文献

被引文献

相似文献

血液学研讨会50周年与圣裘德儿童研究医院50周年同时举行,这两个里程碑都与有助于治愈儿童急性淋巴细胞白血病(ALL)的研究有着不可分割的联系。因此,我们认为,通过回到过去来纪念这些事件是合适的,以指出一些成就,机构,研究小组和个人,使治愈儿童成为现实。在许多情况下,进展是由新的想法驱动的,而在其他情况下,它是由新的实验工具驱动的,这些工具可以更精确地评估白血病原始细胞的生物学及其在选择治疗中的效用。我们还讨论了一些当代的进步,指出了令人兴奋的未来方向。无论采取何种途径,一个明确的挑战将是使用新兴的基于基因组或基于免疫的治疗方案,以增强而不是复制或损害经典细胞毒性化疗的近期成果。这次旅程的主题提醒人们,任何针对急性淋巴细胞白血病(ALL)等灾难性疾病的研究都是主要成分。这是一小群研究人员的大胆,他们面对儿童癌症的目标是治愈,而不是缓解,作为他们的心态。
The 50th anniversary of Seminars in Hematology coincides with the 50th of St. Jude Children’s Research Hospital, and both milestones are inexorably linked to studies contributing to the cure of childhood acute lymphoblastic leukemia (ALL). We thought it fitting, therefore, to mark these events by traveling back in time to point out some of the achievements, institutions, study groups and individuals that have made cure of childhood ALL a reality. In many instances, progress was driven by new ideas, while in others it was driven by new experimental tools that allowed more precise assessment of the biology of leukemic blasts and their utility in selecting therapy. We also discuss a number of contemporary advances that point the way to exciting future directions. Whatever pathways are taken, a clear challenge will be to use emerging genome-based or immunologic-based treatment options in ways that will enhance, rather than duplicate or compromise, recent gains in outcome with classic cytotoxic chemotherapy. The theme of this journey serves as a reminder of the chief ingredient of any research directed to a catastrophic disease such as ALL. It is the audacity of a small group of investigators who confronted a childhood cancer with the goal of cure, not palliation, as their mindset.
DOI: 10.1038/leu.2012.26
发表时间: 2012-07-01
期刊: LEUKEMIA
影响因子: 11.4
作者:
Chen, B.;Wang, Y-Y;Chen, S-J
通讯作者: Chen, S-J
DOI: 10.1016/s1470-2045(08)70339-5
发表时间: 2009-02
期刊: LANCET ONCOLOGY
影响因子: 51.1
作者:
Den Boer, Monique L.;van Slegtenhorst, Marjon;De Menezes, Renee X.;Cheok, Meyling H.;Buijs-Gladdines, Jessica G. C. A. M.;Peters, Susan T. C. J. M.;Van Zutven, Laura C. M.;Beverloo, H. Berna;Van der Spek, Peter J.;Escherich, Gaby;Horstmann, Martin A.;Janka-Schoub, Gritta E.;Kamps, Willem A.;Evans, William E.;Pieters, Rob
通讯作者: Pieters, Rob
DOI: 10.1038/leu.2011.227
发表时间: 2012-02
期刊: Leukemia
影响因子: 11.4
作者:
通讯作者: --
DOI: 10.1093/jnci/djs344
发表时间: 2012-09-01
影响因子: 10.3
作者:
Conklin, H. M.;Krull, K. R.;Pui, C. H.
通讯作者: Pui, C. H.
DOI: 10.1182/blood-2011-11-394221
发表时间: 2012-04-12
期刊: BLOOD
影响因子: 20.3
作者:
Chen, I. Ming;Harvey, Richard C.;Willman, Cheryl L.
通讯作者: Willman, Cheryl L.